Shanghai MicroPort Endovascular MedTech Future Growth
Future criteria checks 3/6
Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 18.9% and 26.8% per annum respectively. EPS is expected to grow by 19.2% per annum. Return on equity is forecast to be 17.2% in 3 years.
Key information
18.9%
Earnings growth rate
19.2%
EPS growth rate
| Medical Equipment earnings growth | 25.7% |
| Revenue growth rate | 26.8% |
| Future return on equity | 17.2% |
| Analyst coverage | Good |
| Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Shares Lagging The Market But So Is The Business
Jan 03
Investors Met With Slowing Returns on Capital At Shanghai MicroPort Endovascular MedTech (SHSE:688016)
Dec 16Calculating The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)
Nov 27Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders
Nov 06There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise
Oct 01Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts
Aug 29Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends
Aug 15Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel
Jun 29These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely
Apr 29Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem
Apr 09Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't
Mar 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,232 | 941 | 486 | 901 | 8 |
| 12/31/2025 | 1,718 | 733 | 289 | 701 | 9 |
| 12/31/2024 | 1,282 | 590 | 184 | 545 | 6 |
| 9/30/2024 | 1,268 | 657 | 390 | 606 | N/A |
| 6/30/2024 | 1,353 | 616 | 437 | 636 | N/A |
| 3/31/2024 | 1,260 | 552 | 458 | 651 | N/A |
| 12/31/2023 | 1,187 | 492 | 368 | 558 | N/A |
| 9/30/2023 | 1,121 | 444 | 166 | 398 | N/A |
| 6/30/2023 | 1,059 | 421 | 22 | 369 | N/A |
| 3/31/2023 | 924 | 358 | -10 | 308 | N/A |
| 12/31/2022 | 897 | 357 | 40 | 334 | N/A |
| 9/30/2022 | 839 | 367 | 133 | 340 | N/A |
| 6/30/2022 | 781 | 346 | 276 | 362 | N/A |
| 3/31/2022 | 745 | 338 | 242 | 337 | N/A |
| 12/31/2021 | 685 | 316 | 211 | 300 | N/A |
| 9/30/2021 | 652 | 302 | 248 | 299 | N/A |
| 6/30/2021 | 618 | 279 | 255 | 291 | N/A |
| 3/31/2021 | 569 | 257 | 239 | 269 | N/A |
| 12/31/2020 | 470 | 215 | 191 | 217 | N/A |
| 9/30/2020 | 414 | 192 | 148 | 174 | N/A |
| 6/30/2020 | 377 | 177 | 142 | 166 | N/A |
| 3/31/2020 | 341 | 156 | 133 | 154 | N/A |
| 12/31/2019 | 334 | 142 | 122 | 143 | N/A |
| 9/30/2019 | 306 | 127 | 117 | 138 | N/A |
| 6/30/2019 | 282 | 115 | 84 | 117 | N/A |
| 3/31/2019 | 257 | 103 | 90 | 118 | N/A |
| 12/31/2018 | 231 | 91 | 82 | 107 | N/A |
| 12/31/2017 | 165 | 63 | N/A | 69 | N/A |
| 12/31/2016 | 125 | 41 | N/A | 30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688016's forecast earnings growth (18.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 688016's earnings (18.9% per year) are forecast to grow slower than the CN market (25.2% per year).
High Growth Earnings: 688016's earnings are forecast to grow, but not significantly.
Revenue vs Market: 688016's revenue (26.8% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 688016's revenue (26.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688016's Return on Equity is forecast to be low in 3 years time (17.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 21:31 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai MicroPort Endovascular MedTech Co., Ltd. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jian Jun Zou | Chasing Securities |
| Jingning Long | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |